NONCOMPARTMENTAL ANALYSIS

Slides:



Advertisements
Similar presentations
Karunya Kandimalla, Ph.D
Advertisements

PHARMACOKINETIC MODELS
HEPATIC CLEARANCE Q x CA Q x CV Q(CA - CV) 1. Mass Balance
Non-compartmental analysis and The Mean Residence Time approach
Clinical Pharmacokinetics
PHARMACOKINETIC.
The half-life OCT 2010.
SEMINAR ON NONCOMPARTMENTAL PHARMACOKINETICS
Non compartmental analysis
Nonlinear pharmacokinetics
One-compartment open model: Intravenous bolus administration
Week 3 - Biopharmaceutics and Pharmacokinetics
Laplace transformation
Practical Pharmacokinetics
Week 4 - Biopharmaceutics and Pharmacokinetics
Toxicokinetic Calculations
Gokaraju Rangaraju College of Pharmacy
INTRAVENOUS INFUSION.
CLEARANCE CONCEPTS Text: Applied Biopharm. & PK
CLEARANCE (CL) describes the efficiency of irreversible elimination of a drug from the body by excretion of unchanged drug. Metabolic conversion of the.
University of Jordan-Faculty of Pharmacy
Quantitative Pharmacokinetics
Principles of Clinical Pharmacology Noncompartmental versus Compartmental Approaches to Pharmacokinetic Data Analysis David Foster, Professor Emeritus.
Pharmacokinetics Introduction
From A Physiologic Perspective Chemical Clearance from the Body
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
PHARMACOKINETIC MODELS
Touqeer Ahmed Ph.D. Atta-ur-Rahman School of Applied Bioscience, National University of Sciences and Technology 21 st October, 2013.
1-Compartment Oral Dosing 400 mg of moxifloxacin is administered orally to Mr BB, a 68 yr old male who weighs 75 kg. Blood samples were drawn following.
Area under the plasma concentration time curve. IMPORTANCE OF AUC Pharmacokinetics - measurement of bioavaibility absolute, relative Biopharmaceutics.
Biopharmaceutics refers to the relationship of the:
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
One Compartment Open Model IV bolus
The General Concepts of Pharmacokinetics and Pharmacodynamics
Noncompartmental Models. Introduction The noncompartmental approach for data analysis does not require any specific compartmental model for the system.
Continuous intravenous infusion (one-compartment model)
BIOPHARMACEUTICS.
1 Pharmacokinetics: Introduction Dr Mohammad Issa.
Phoenix WinNonLin Assignment Due Today Access Phoenix remotely.
ــــــــــــــ February 17 th, PHT - LECTURE Mathematical Fundamental in Pharmacokinetics Dr. Ahmed Alalaiwe.
PHT 415 BASIC PHARMACOKINETICS
Time Plasma Conc (hr) (mg/L) Below limit of detection 1 Compartment IV Analysis & Renal Elimination 500 mg of tobramycin.
1 CHAPTER 2 DEFINITIONS RELATED TO PHARMACOKINETICS.
Pharmacokinetics 3rd Lecture
MULTIPLE DOSAGE REGIMEN
Compartmental Models and Volume of Distribution
Allie punke Pharmacokinetics tutoring Fall 2016
Physiology for Engineers
Allie punke Pharmacokinetics tutoring Fall 2016
Chapter 8 BIOAVAILABILITY & BIOEQUIVALENCE
Chapter 7 COMPARTMENT MODELS
Lecture-8 Biopharmaceutics
Pharmacokinetic Modeling (describing what happens)
Dosing Regimen Concepts: 2-C, MM, Individualization principles
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Lab-3 practical pharmacology
Quantitative Pharmacokinetics
Biopharmaceutics Dr Mohammad Issa Saleh.
Clinical Pharmacokinetics
Clinical Pharmacokinetics
Hawler Medical University
Biopharmaceutics Chapter-6
Hawler Medical University
Therapeutic Drug Monitoring chapter 1 part 1
Clinical Pharmacokinetics
1-C: Renal and Hepatic Elimination
Q1: Drug A is a small and hydrophilic compound that distributes to extracellular fluids only. It has a volume of distribution of 5.6 L in a healthy 70-kg.
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Presentation transcript:

NONCOMPARTMENTAL ANALYSIS Deficiencies of compartmental analysis: Lack of meaningful physiological basis for derived parameters. Lack of rigorous criteria to determine # of compartments necessary to describe disposition. Lack of ability to elucidate organ specific elimination. Inability to relate derived parameters to quantifiable physiological parameters. Inability to predict impact of pathophysiology. Inability to provide insight into mechanism of drug-drug and drug-nutrient interactions. Highly sensitive to sampling frequency.

GENERAL PRINCIPLES OF STATISTICAL MOMENTS MOMENT: A mathematical description of a discrete distribution. STATISTICAL MOMENTS: Utilized in chemical engineering to describe flow data First applied to biological systems by Perl and Samuel in 1969 to describe the kinetics of cholesterol

Examples of Statistical Moment Usage In statistics In physics weight N M0 (mean) Center of mass M1 (variance) Moment of inertia M2 (skewness) M3 (kurtosis) M4

In statistics, the mean is a measure of a sample mean and is actually an estimate of the true population mean. In pharmacokinetics, we can calculate the moment of the theoretical probability density function (i.e., the solution of a differential equation describing the plasma concentration time data), or we can calculate moments from measured plasma concentration-time data. These curves are referred to as sample moments and are estimates of the true curves.

Assume a theoretical relationship of C(t) as a function of time Assume a theoretical relationship of C(t) as a function of time. The non-normalized moments, Sr , about the origin are calculated as:

AUC AUMC Non-normalized moments Kinetic parameter Area under the curve Area under the moment curve

From: Rowland M, Tozer TN From: Rowland M, Tozer TN. Clinical Pharmacokinetics – Concepts and Applications, 3rd edition, Williams and Wilkins, 1995, p. 487.

Normalized moments Kinetic parameter First moment: MRT Mean residence time

AREA DETERMINATION A. Integration of Specific Function Must elucidate the specific function Influenced by the quality of the fit

B. Numerical Integration Linear trapezoidal Log trapezoidal

B. Numerical Integration Linear trapezoidal

B. Numerical Integration Linear trapezoidal Advantages: Simple (can calculate by hand) Disadvantages: Assumes straight line btwn data points If curve is steep, error may be large Under or over estimate depends on whether curve is ascending of descending

B. Numerical Integration Linear trapezoidal Log trapezoidal

B. Numerical Integration Linear trapezoidal Log trapezoidal Advantages: Hand calculator Very accurate for mono-exponential Very accurate in late time points where interval btwn points is substantially increased Disadvantages: Limited application May produce large errors on an ascending curve, near the peak, or steeply declining polyexponential curve

B. Numerical Integration Linear trapezoidal Log trapezoidal Extrapolation to infinity Assumes log-linear decline

AUMC Determination AUC Determination C x t (mg/L)(hr) 2.00 3.39 3.50 3.01 0.45 Area (mg-hr2/L) - 1.00 5.39 6.89 6.51 7.52 9.80 37.11 Time (hr) C (mg/L) 0 2.55 1 2.00 3 1.13 5 0.70 7 0.43 10 0.20 18 0.025 Area (mg-hr/L) - 2.275 3.13 1.83 1.13 0.945 0.900 Total 10.21

CLEARANCE CONCEPTS Q Q ORGAN Cv Ca elimination If Cv < Ca, then it is a clearing organ

Rate In = QCa Rate Out = QCv Rate of elimination = QCa – QCv = Q(Ca – Cv)

Extraction Ratio: Ratio of the rate of xenobiotic elimination and the rate at which xenobiotic enters the organ.

Clearance: The volume of blood from which all of the drug would appear to be removed per unit time.

Relationship between CL & Q Since CL = QE, if E~1: CL Q Perfusion rate-limited clearance

Total Clearance Total (systemic) Clearance:

Total Clearance Total (systemic) Clearance:

Additivity of clearance Rate of elimination = Rate of Renal Excretion + Rate of Hepatic Metabolism Dividing removal rate by incoming concentration: Total Clearance = Renal Clearance + Hepatic Clearance CLT = CLR + CLH

Exception: sig. pulmonary elimination From: Rowland M, Tozer TN. Clinical Pharmacokinetics – Concepts and Applications, 3rd edition, Williams and Wilkins, 1995, p. 12.

100 mg drug administered to a volunteer resulted in 10 mg excreted in urine unchanged:

Application of Clearance Concepts Prediction of the effect of pathophysiological changes A new antibiotic has just been introduced onto the market. Currently, there are no studies examining the effect of renal disease on the pharmacokinetics of this compound. Is dosage adjustment necessary for this drug when used in pts with renal failure? How can we gain some insight into this question? A study in normal volunteers was recently published and the following data was included (mean):

Application of Clearance Concepts Prediction of the effect of pathophysiological changes CLT = 1.2 L/hr Div = 500 mg Amount in urine unchanged = 63 mg

Mechanisms of altered elimination Verapamil has been shown to elevate serum digoxin concentrations in patients receiving both drugs concurrently. A study by Pedersen et al (Clin Pharmacol Ther 30:311-316, 1981.) examined this interaction with the following results.: Treatment Digoxin Dig + verapamil CLT 3.28 2.17 CLR 2.18 1.73 CLNR 1.10 0.44

STEADY-STATE VOLUME OF DISTRIBUTION VP VT Cf Cf Cbp Cbt

VP VT Cf Cf Cbp Cbt CP = Cf + Cbp CT = Cf + Cbt

At steady-state: Substitute:

Simplifying:

Using blood concentrations:

Calculation via moment analysis: Assumptions: Linear disposition Administered and eliminated via sampling site Instantaneous input

If administration via a short term infusion: K0 = infusion rate T = infusion duration

MEAN RESIDENCE/TRANSIT TIME Administration of a small dose may represent a large number of molecules: Dose = 1 mg MW = 300 daltons # of molecules = (10-3 g/300) x (6.023 x 1023) ~2 x 1018 molecules

Instantaneous administration of the entire dose will result in xenobiotic molecules spending various amounts of time in the body. Evaluation of the time various molecules spend in the body (residence time) can be characterized in the same manner as any statistical distribution. Mean residence time: The average time the molecules of a given dose spend in the body.

A conceptual understanding can be gained from the following example: Assume a child received 20 dimes for his birthday and immediately places them in his piggy bank. Over the next month, he periodically removes 1 or more dimes from the piggy bank to purchase candy. Specifically, 3 days after placing the coins in his bank he removes 5 dimes, on day 10 he removes 4 dimes, on day 21 he removes 6 dimes and on day 30 he removes 5 dimes. At the 30th day after placing the coins in his bank, all of the coins have been removed. Hence, the elimination of the deposited dimes is complete. The MRT of the dimes in the piggy bank is simply the sum of the times that coins spend in the bank divided by the number of dimes placed in the bank.

MRT can be determined for any given number of drug molecules (Ai) that spend a given amount of time (ti) in the body:

The mean rate of drug leaving the body relative to the total amount eliminated can be expressed in terms of concentration:

This is not a definition of MRT, rather it is a means of calculating MRT when CL is constant. When calculated in this fashion, it is often said that MRT is a function of the route of administration. However, MRT is independent of the route. Meant Transit Time (MTT): The average time for xenobiotic molecules to leave a kinetic system after administration.

Since an iv bolus assumes instantaneous input:

If drug declines via monoexponential decline:

SYSTEMIC AVAILABILITY